| Two-year course of subfoveal pigment epithelial detachment in eyes with age-related macular degeneration and visual acuity better than 20/40. | |
| | |
MedLine Citation:
|
PMID: 22508168 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: To investigate the course of subfoveal pigment epithelial detachments (PEDs) in eyes with age-related macular degeneration (AMD) and best-corrected visual acuity (BCVA) ≥20/40. METHODS: Thirty-seven eyes of 35 patients with a subfoveal PED were divided into an avascular PED group (n = 11), a vascularized PED group due to polypoidal choroidal vasculopathy (PCV, n = 14) and an occult choroidal neovascularization (CNV) group (n = 12). Intravitreal bevacizumab or ranibizumab was given as needed. The BCVA, central foveal thickness, PED thickness, and lesion size were measured at baseline and at 2 years after the initial examination. RESULTS: The BCVA did not change significantly in the avascular group, decreased from 0.06 ± 0.11 to 0.23 ± 0.15 logMAR units in the PCV group and from 0.12 ± 0.12 to 0.71 ± 0.70 logMAR units in the CNV group. At 2 years, the central foveal and PED thicknesses were not significantly different among the 3 groups, and the lesion was significantly larger in the PCV and CNV groups than in the avascular group. CONCLUSIONS: The vascularized PED cases had a poorer visual outcome than avascular PEDs with anti-VEGF drugs at the 2-year follow-up. |
| | |
Authors:
|
Takayuki Baba; Masayasu Kitahashi; Mariko Kubota-Taniai; Toshiyuki Oshitari; Shuichi Yamamoto |
Related Documents
:
|
6732578 - Treatment of xerophthalmia with retinol, tretinoin, and etretinate. 23204608 - Occurrence of epilepsy at different zeitgeber times alters sleep homeostasis differentl... 21838198 - Anti-oxidant treatment in obstructive sleep apnoea syndrome. 10872918 - Effect of sr121463, a selective non-peptide vasopressin v2 receptor antagonist, in a ra... 10488278 - Anesthesia considerations for patients with narcolepsy. 14592258 - Excessive fragmentary hypnic myoclonus: clinical and neurophysiological findings. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2012-04-13 |
Journal Detail:
|
Title: Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde Volume: 228 ISSN: 1423-0267 ISO Abbreviation: Ophthalmologica Publication Date: 2012 |
Date Detail:
|
Created Date: 2012-07-31 Completed Date: 2012-10-05 Revised Date: 2013-05-27 |
Medline Journal Info:
|
Nlm Unique ID: 0054655 Medline TA: Ophthalmologica Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 102-9 Citation Subset: IM |
Copyright Information:
|
Copyright © 2012 S. Karger AG, Basel. |
Affiliation:
|
Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba, Japan. babatakayuki@nifty.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Angiogenesis Inhibitors / administration & dosage Antibodies, Monoclonal, Humanized / administration & dosage Choroid / blood supply Choroid Diseases / diagnosis, drug therapy, physiopathology Choroidal Neovascularization / diagnosis, drug therapy, physiopathology Female Fluorescein Angiography Follow-Up Studies Fovea Centralis Humans Indocyanine Green / diagnostic use Intravitreal Injections Macular Degeneration / diagnosis, drug therapy, physiopathology* Male Polyps / diagnosis, drug therapy, physiopathology Retinal Detachment / diagnosis, drug therapy, physiopathology* Retinal Pigment Epithelium Tomography, Optical Coherence Vascular Endothelial Growth Factor A / antagonists & inhibitors Visual Acuity / physiology* |
| Chemical | |
Reg. No./Substance:
|
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 0/ranibizumab; 2S9ZZM9Q9V/bevacizumab; 3599-32-4/Indocyanine Green |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Conduit diameter and wall remodeling in elite athletes and spinal cord injury.
Next Document: Is isoniazid for 6 months more cost-effective than isoniazid for 9 months?